NDA 018749 · Mission Pharma
Lithostat
Acetohydroxamic Acid · Oral · Urease Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Jan 26, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1983
May 31, 1983
Approved uses
1
Original approval plus efficacy supplements
Registered trials
3
0 Phase 3, 0 recruiting
FAERS reports
47
11 serious, 5 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 8, 2026.
INDICATIONS AND USAGE Acetohydroxamic acid is indicated as adjunctive therapy in patients with chronic urea-splitting urinary infection. AHA is intended to decrease urinary ammonia and alkalinity, but it should not be used in lieu of curative surgical treatment (for patients with stones) or antimicrobial treatment. Long-term treatment with AHA may be warranted to maintain urease inhibition as long as urea-splitting infection is present. Experience with AHA does not go beyond 7 years. A patient package insert should be distributed to each patient who receives AHA.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 31, 1983 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- LITHOSTAT · ACETOHYDROXAMIC ACID 250MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Acetohydroxamic Acid" as an intervention, any sponsor and status, largest first.
- Acetohydroxamic Acid Combined With a Short-Course Regimen for MDR-TB (AHA-PLUS)Pivotal-lookingNot yet recruiting
Shanghai Pulmonary Hospital, Shanghai, ChinaAcademic, hospital or other
NCT07393438 · 120 participants (planned) · Start Feb 21, 2026 · Primary completion Feb 28, 2027
Drug: Acetohydroxamic Acid; Placebo · For: Multidrug-Resistant Tuberculosis; Rifampicin-resistant Tuberculosis; MDR-TB and 1 more
Sites: Hefei, China; Shanghai, China
Austin Institute for Clinical ResearchResearch network
NCT05908825 · 34 participants · Start Jun 22, 2023 · Primary completion Nov 16, 2023
Drug: Vitamin C with AHA Exfoliative Serum; Placebo serum · For: Photodamaged Skin
Sites: Pflugerville, Texas
- Manipulating the Gut Microbiome StudyTerminated
Nicholas Ah MewAcademic, hospital or other
NCT03181828 · 4 participants · Start Mar 24, 2017 · Primary completion Jun 5, 2018
Drug: Acetohydroxamic Acid Oral Tablet · For: Urea Cycle Disorder
Sites: Washington D.C., District of Columbia
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- headache12
- decreased appetite10
- tremor9
- asthenia5
- nausea5
- confusional state4
- death4
- fatigue4
- rash4
- somnolence4
- abdominal pain upper3
- alopecia3
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 2 |
| 2013 | 1 |
| 2016 | 3 |
| 2017 | 13 |
| 2018 | 12 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 6 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Lithostat (Acetohydroxamic Acid)
2024 spending
$651K
Beneficiaries
242
1,360 claims
Per beneficiary
$2,688
$6.73 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $742,914 |
| 2021 | $973,033 |
| 2022 | $701,602 |
| 2023 | $572,333 |
| 2024 | $650,584 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Prevention of Recurrent Nephrolithiasis in Adults and Children : A Systematic Review.
Asher GN, Viprakasit DP, Aymes SE, et al. · Ann Intern Med 2026 · Systematic Review
- Effect of acetohydroxamic acid on dissolution of canine struvite uroliths.
Krawiec DR, Osborne CA, Leininger JR, et al. · Am J Vet Res 1984 · Controlled Clinical Trial, Research Support, Non-U.S. Gov't
- A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis.
Williams JJ, Rodman JS, Peterson CM · N Engl J Med 1984 · Clinical Trial, Randomized Controlled Trial
- Effect of acetohydroxamic acid on prevention of canine struvite uroliths.
Krawiec DR, Osborne CA, Leininger JR, et al. · Am J Vet Res 1984 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Randomized, double-blind trial of Lithostat (acetohydroxamic acid) in the palliative treatment of infection-induced urinary calculi.
Griffith DP, Gleeson MJ, Lee H, et al. · Eur Urol 1991 · Clinical Trial, Comparative Study
- A randomized trial of acetohydroxamic acid for the treatment and prevention of infection-induced urinary stones in spinal cord injury patients.
Griffith DP, Khonsari F, Skurnick JH, et al. · J Urol 1988 · Clinical Trial, Randomized Controlled Trial
Sponsor: Mission Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.